Myriad Genetics, Inc., has announced new clinical data from a study involving the company’s myRisk Hereditary Cancer. In the study, the 25-gene hereditary cancer panel showed a 60% increase in mutations detected in cancer predisposition genes in patients with a history of colon cancer and/or polyps. Myriad is presenting this clinical study this week at the Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA) annual meeting in Anaheim, CA.
“The new data presented at this year's CGA meeting is groundbreaking and underscores the importance of using multi-gene panels when testing patients for hereditary colon cancer,” says Richard J. Wenstrup, MD, chief medical officer of Myriad. “Importantly, the data suggest that the use of a 25-gene hereditary cancer panel significantly improved the detection of mutations and is a more efficient way for patients to receive appropriate medical management.”
Myriad is also presenting four other clinical studies involving Lynch syndrome, the most common genetic cause of colon cancer: “Overlap between Lynch Syndrome and Hereditary Breast and Ovarian Cancer Syndrome among Family Histories in Patients Tested for Hereditary Cancer Syndromes”; “MSI-High Histology Is a Predictive Risk Factor for Lynch Syndrome”; ”Mutation Breakdown and Variant Rates in Lynch Syndrome”; “Clinical Presentation of Monoallelic MUTYH Mutation Carriers in a Select Population.” Learn more about hereditary cancer testing products offered by this company.
